Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Scinai Immunotherapeutics ( (SCNI) ) has issued an update.
On February 25, 2026, Scinai Immunotherapeutics announced that the Israel Innovation Authority has expanded support for the company’s project to implement a robotic aseptic fill-and-finish platform, allowing Scinai to deploy the full NIS 5 million two-year grant budget, roughly two-thirds of which is non-dilutive. The investment will fund acquisition and validation of an automated robotic-arm aseptic system aligned with EU GMP Annex 1, with validation targeted by the third quarter of 2026.
The platform is intended to enhance sterile manufacturing by reducing human intervention, improving batch consistency, and tightening contamination control, thereby strengthening Scinai’s clinical manufacturing capabilities at its Jerusalem biologics site. Together with the recent acquisition of Recipharm Israel and the commercial collaboration with Recipharm, the move deepens Scinai’s technology base and supports its strategy to scale a two-site CDMO platform, while the company also monitors potential new Israel Innovation Authority programs that could further upgrade its Yavne small-molecule facility.
The most recent analyst rating on (SCNI) stock is a Hold with a $0.98 price target. To see the full list of analyst forecasts on Scinai Immunotherapeutics stock, see the SCNI Stock Forecast page.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
The score is held back primarily by weak financial performance—persistent operating losses and continued cash burn despite recent balance sheet improvement. Technicals are a moderate positive with the stock trading above key short-term averages and mildly positive momentum, while valuation is constrained by a negative P/E and no dividend support.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside a focused immunology R&D pipeline. Its wholly owned CDMO unit runs biologics development and clinical manufacturing in Jerusalem and small-molecule API development and GMP production in Yavne, serving early-stage biotech and mid-size pharmaceutical clients from preclinical work through Phase I/II clinical supply.
Through a strategic commercial collaboration with Recipharm, Scinai offers customers a defined route from early clinical development to late-stage and commercial manufacturing within Recipharm’s global network, aiming to streamline tech transfer and reduce scale-up risk. In parallel, its R&D arm is advancing programs such as PC111, an anti-FasL monoclonal antibody for orphan dermatologic indications, and NanoAb-based inflammation therapies, for which it is pursuing partnerships and regional licensing deals.
Average Trading Volume: 49,882
Technical Sentiment Signal: Sell
Current Market Cap: $732.7K
Learn more about SCNI stock on TipRanks’ Stock Analysis page.